In vitro evaluation of lomefloxacin activity in Colombia.
As part of the worldwide in vitro program to determine the antimicrobial activity of lomefloxacin, our study tested susceptibility of bacterial isolates from hospitals in Medellin, Colombia. A total of 504 bacterial isolates were obtained from patients at three different centers. For Enterobacteriaceae, 0.5 micrograms/ml inhibited 100% of the indole-positive Proteus and Salmonella spp.; 1 microgram/ml inhibited 100% of Shigella and Citrobacter, 2 microgram/ml inhibited 100% of Enterobacter spp., E. coli, Proteus mirabilis, and Serratia marcescens isolates tested. The MIC90 for Klebsiella spp. and Pseudomonas spp. was 4 micrograms/ml. The MIC90 was 4 micrograms/ml for S. aureus and 2 micrograms/ml for S. epidermidis and S. saprophyticus. The MIC90 of Streptococcus spp. were less than or equal to 4 micrograms/ml for all isolates tested. Considering that 97.8% were susceptible to concentrations of less than or equal to 4 micrograms/ml of lomefloxacin, this new quinolone offers potential in the therapy of a variety of systemic infections, especially in patients with multiply resistant pathogens.